Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

Dogs share our homes, our habits and sometimes, our diseases. Gastric cancer is rare in dogs, but when it does strike, it ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Zoetis launches AI Masses, the new AI-powered cytologic capability for Vetscan Imagyst. News release. Zoetis. June 2, 2025.

It can linger in the environment and harm biodiversity, contributing to food insecurity and economic losses. Researchers ...

ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

Dogs share our homes, our habits and sometimes, our diseases. Gastric cancer is rare in dogs, but when it does strike, it ...

BCG is an immunotherapy treatment. Medicare may cover BCG when medically necessary to treat certain types of bladder cancer or after a transurethral resection of bladder tumor (TURBT). Original ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. The clinical ...